Pre-treatment with clopidogrel and postprocedure troponin elevation after elective percutaneous coronary intervention

Summary

Elevated troponin after elective percutaneous coronary intervention (PCI) has been associated with a worse prognosis. Pretreatment with clopidogrel may be beneficial in patients undergoing PCI. Therefore, a prospective observational study was conducted to address the potential role of clopidogrel in reducing troponin release after elective PCI. TroponinT was measured 12 hours after elective PCI in 656 patients without elevated troponin before PCI. To assess the independent association between pre-treatment with clopidogrel and increased troponin, multivariate analyses were performed. Mean age of the 656 patients was 63.5 years (SD 10.2), 194 patients (30%) were female and 114 patients (17.4%) had diabetes. In 217 patients (33%) troponin was increased after PCI. Of the 330 patients who were not pre-treated with clopidogrel, 118 patients (34%) had increased troponin after the PCI compared to 99 patients (30%) of the 326 patients who were treated with clopidogrel longer than 24 hours before the procedure (p=0.14). Stratified analyses showed that patients with older age (p=0.03), previous PCI (p=0.013), angina CCS 4 (p=0.03) and multivessel disease (p=0.04) had a significantly lower risk of troponin increase after pre-treatment with clopidogrel compared to patients without pre-treatment. After adjusting for differences in the other variables, patients who were pre-treated with clopidogrel had a significant lower risk of post-PCI increase of troponinT (odds ratio 0.69, 95% confidence interval 0.49–0.99). Pre-treatment with clopidogrel is associated with a significantly lower incidence of increased troponin after elective PCI. Combined with results of other studies, pre-treatment should be advised in patients waiting for elective PCI.

Keywords

Clopidogrel - troponin - percutaneous coronary intervention

• References

• 1 Silber S. et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur HeartJ 2005; 26: 804-47.
• 2 Popma JJ. et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 576S-99S.
• 3 Levine GN. et al. Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med 2003; 139: 123-36.
• 4 Chan AW. et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival. J Am Coll Cardiol 2003; 42: 1188-99.
• 5 Mehta SR. et al. Effects of pretreatment with clopidogrel and aspirin followed by a long term therapy in patients undergoing percutaneous coronary intervention; the PCI-CURE study. Lancet 2001; 358: 527-33.
• 6 Berglund U, Richter A. Clopidogrel treatment before percutaneous coronary intervention reduces adverse cardiac events. J Invasive Cardiol 2002; 14: 243-6.
• 7 Steinhubl SR. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention, a randomized controlled trial (CREDO). JAMA 2002; 288: 2411-20.
• 8 Kandzari DE. et al. Influence of treatment duration witha 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44: 2133-6.
• 9 van der Heijden DJ. et al. Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J Am Coll Cardiol 2004; 44: 20-4.
• 10 Wu AH. et al. Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. Am J Cardiol 2002; 89: 1300-2.
• 11 Nageh T. et al. Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease. Heart 2005; 91: 1181-5.
• 12 Mandadi VR. et al. Predictors of troponin elevation after percutaneous coronary intervention. Am J Cardiol 2004; 93: 747-50.
• 13 Gurbel PA. et al. Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am HeartJ 2003; 145: 239-47.
• 14 Hochholzer W. et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 2560-4.
• 15 Gurbel PA. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
• 16 Weltermann A. et al. Effects of pretreatment with clopidogrel on platelet and coagulation activation in patients undergoing elective coronary stenting. Thromb Res 2003; 112: 19-24.
• 17 Angiolillo DJ. et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-10.
• 18 Quinn MJ. et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679-84.
• 19 Patti G. et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-106.
• 20 Tardiff BE. et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 1999; 33: 88-96.
• 21 Abdelmeguid AE. et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528-36.
• 22 Akkerhuis KM. et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different ?. Circulation 2002; 105: 554-6.